AiCuris GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:AiCuris GmbH & Co KG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5142
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
AiCuris GmbH & Co KG (AiCuris) a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents for the treatment of severe and life-threatening infectious diseases. It offers drugs for the treatment of human cytomegalovirus, herpes simplex virus, hepatitis B virus and human immunodeficiency virus. The company works in partnership with other drug development companies for the development of medicines targeting human cytomegalovirus. It operates research facility in Wuppertal. AiCuris is headquartered in Wuppertal, Germany.

AiCuris GmbH & Co KG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Ligand Pharma Enters into Agreement with AiCuris 10
AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 11
Licensing Agreements 13
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 13
AiCuris GmbH & Co KG – Key Competitors 15
AiCuris GmbH & Co KG – Key Employees 16
AiCuris GmbH & Co KG – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Key Facts 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AiCuris GmbH & Co KG, Deals By Therapy Area, 2012 to YTD 2018 8
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ligand Pharma Enters into Agreement with AiCuris 10
AiCuris Enters Into Drug Discovery Agreement With 4SC Discovery And Crelux 11
Merck Enters Into Licensing Agreement With AiCuris For Investigational Portfolio Targeting Human Cytomegalovirus 13
AiCuris GmbH & Co KG, Key Competitors 15
AiCuris GmbH & Co KG, Key Employees 16

List of Figures
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
AiCuris GmbH & Co KG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[AiCuris GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • HSBC Holdings Plc:企業の戦略・SWOT・財務情報
    HSBC Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary HSBC Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • InterOil Exploration & Production ASA Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    InterOil Exploration & Production ASA Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary InterOil Exploration & Production ASA (InterOil Exploration & Production) is an oil and gas company that provides petroleum exploration services. The company acquires, explores, …
  • Sensient Technologies Corp (SXT):企業の財務・戦略的SWOT分析
    Sensient Technologies Corp (SXT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • National Cancer Centre Singapore-製薬・医療分野:企業M&A・提携分析
    Summary National Cancer Centre Singapore (NCCS) is a healthcare service provider that offers research and cancer treatment services. The center offers research for cancers such as breast, gynaecology, haematology, head and neck, neuro oncology, naso pharynx cancer, paediatrics, reconstructive, hepat …
  • Kiniksa Pharmaceuticals Ltd (KNSA):製薬・医療:M&Aディール及び事業提携情報
    Summary Kiniksa Pharmaceuticals Ltd (Kiniksa Pharmaceuticals) is a clinical-stage biopharmaceutical company focused on discovery, acquisition, development and commercialization of therapeutic medicines for the treatment of auto inflammatory and autoimmune diseases. Its pipeline product portfolio inc …
  • QuikTrip Corporation:企業の戦略的SWOT分析
    QuikTrip Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Tandem Diabetes Care Inc (TNDM):企業の財務・戦略的SWOT分析
    Summary Tandem Diabetes Care Inc (Tandem) is a medical device manufacturing company that designs and develops diabetic care products. The company's product portfolio includes t:slim X2 insulin pump, basal-IQ technology, software and applications, infusion sets and other pump accessories. It also pro …
  • Revera Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Revera Inc (Revera), formerly Retirement Residences Real Estate Investment Trust, is a healthcare service provider that offers assisted living, independent living, seniors’ apartments,memory care and long term care services. The center provides person-centered care, quality care, clinical pr …
  • DSW Inc.:企業の戦略・SWOT・財務情報
    DSW Inc. - Strategy, SWOT and Corporate Finance Report Summary DSW Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Hypera SA:企業の戦略・SWOT・財務情報
    Hypera SA - Strategy, SWOT and Corporate Finance Report Summary Hypera SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Ineos Group AG:石油・ガス:M&Aディール及び事業提携情報
    Summary Ineos Group AG (Ineos), a subsidiary of INEOS Group Holdings SA, is a chemical manufacturing company. It manufactures and sells petrochemicals, specialty chemicals and oil products. The company’s products include ammonia, nitric acid, sea salt, esters, bio fuel, sulphuric acid, amino resin, …
  • Canadian National Railway Co:戦略・SWOT・企業財務分析
    Canadian National Railway Co - Strategy, SWOT and Corporate Finance Report Summary Canadian National Railway Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Sysmex Corp (6869):企業の製品パイプライン分析2018
    Summary Sysmex Corp (Sysmex) is a supplier of medical devices. It researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. The company offers diagnostic instruments, reagents and laboratory inform …
  • Sui Northern Gas Pipelines Ltd (SNGP):企業の財務・戦略的SWOT分析
    Sui Northern Gas Pipelines Ltd (SNGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • George Weston Limited:企業の戦略・SWOT・財務情報
    George Weston Limited - Strategy, SWOT and Corporate Finance Report Summary George Weston Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Flint Group:企業の戦略・SWOT・財務分析
    Flint Group - Strategy, SWOT and Corporate Finance Report Summary Flint Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Jardine Engineering Corporation, Limited:企業の戦略・SWOT・財務情報
    Jardine Engineering Corporation, Limited - Strategy, SWOT and Corporate Finance Report Summary Jardine Engineering Corporation, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Symbiomix Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Symbiomix Therapeutics LLC (Symbiomix) is a drug development company that offers development and commercialization of novel medicines. The company offers SYM-1219, for the treatment of several serious infections in women including bacterial vaginosis. Its SYM-1219 contains secnidazole, nitro …
  • California Resources Corp (CRC):企業の財務・戦略的SWOT分析
    California Resources Corp (CRC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Oncodesign SA (ALONC):製薬・医療:M&Aディール及び事業提携情報
    Summary Oncodesign SA (Oncodesign) is a biopharmaceutical company, specializing in precision medicine offers drug discovery and pharmacological evaluation services for cancer. Its service offerings include integrated drug discovery; metabolic and pharmacokinetic characteristics of chemical and biolo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆